Moderna produces Covid-19 shot targeting variant found in SA
US biotech is preparing for a clinical trial to gauge effectiveness on 501. V2 strain
New York — Moderna has become the first vaccine maker to produce a shot targeted at the virus variant discovered in SA, and will ship the doses to the US National Institutes of Health to prepare for a clinical trial.
The Boston-based biotech is taking a three-pronged strategy to address concerns that its vaccine, along with several others, is less effective against the 501. V2 strain. ..